ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 989

A Randomized Controlled Trial of Rheumatoid Arthritis Risk Disclosure Personalized to Genetics, Autoantibodies, and Lifestyle Among Unaffected First-Degree Relatives: The Personalized Risk Estimator for RA (PRE-RA) Family Study

Jeffrey A. Sparks1, Maura D. Iversen2, Zhi Yu3, Nellie A. Triedman3, Maria G. Prado3, Rachel Miller Kroouze4, Sarah S. Kalia5, Elinor A. Mody3, Simon M. Helfgott3, Derrick J. Todd3, Paul F. Dellaripa3, Bonnie L. Bermas3, Kevin D. Deane6, Karen H. Costenbader3, Bing Lu3, Robert C. Green5 and Elizabeth W. Karlson3, 1Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Physical Therapy, Movement and Rehabilitation Sciences, Northeastern University, Boston, MA, 3Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 6Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: autoantibodies, clinical trials, Genetics and rheumatoid arthritis (RA), Personalized Medicine

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Epidemiology and Public Health I: Inflammatory Arthritis – Risk and Impact

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose : Disclosure of genetic risk information alone has had limited impact on changing health behaviors in research trials. Prior studies have not evaluated whether disclosure of risk personalized to genetics, biomarkers, and lifestyle factors may motivate changes in health behaviors. We performed a randomized controlled trial to test the effect of personalized RA risk disclosure, including genetics and autoantibodies, on willingness to change RA behavioral risk factors among a high-risk population of first-degree relatives (FDRs).

Methods : We developed the Personalized Risk Estimator for RA (PRE-RA) tool as a web-based intervention for use in the PRE-RA Family Study. PRE-RA provides summary estimates of absolute and relative RA risks and educates individuals about their RA risk factors—including HLA-DRB1 genotype results, CCP and RF autoantibody results, lifestyle risk factors (smoking, overweight/obesity, low fish intake, periodontitis), and demographics. We recruited asymptomatic FDRs without RA at a single center and randomized them to receive PRE-RA education alone (n=80) or PRE-RA education with health educator guidance (n=78; total n=158, PRE-RA group), or to receive standard education about RA (n=80, comparison group). We measured willingness to change behaviors based on Prochaska’s Stages of Readiness for Change using validated ladder scales (range 0-10, higher score indicating more willingness to change) at 4 time points: baseline and immediately, 6 weeks, and 6 months after intervention. The primary outcome for willingness to change behaviors was defined as an increase in any ladder scale for 4 modifiable RA risk factors (exercise, diet, dental care, and smoking among current smokers) 6 months after intervention compared to baseline using intention-to-treat (ITT) analysis. Secondary analyses investigated differences among the three study arms.

Results : Among the 238 randomized subjects, 87% were White and 77% were female. The PRE-RA intervention group was older (mean 46.7 years [SD 14.4]) than the comparison group (mean 43.4 years [SD 14.7]). In the primary ITT analysis, 63.9% of the PRE-RA group met the primary outcome, compared to 50.0% in the comparison group (age-adjusted difference 15.8%, 95%CI 2.8-28.8%, p=0.017, Figure). Within the PRE-RA group, the addition of a health educator resulted in no additional effect on willingness to change behaviors beyond the web-based PRE-RA education tool alone (p=0.54 at 6 months after intervention).

Conclusion : Disclosure of RA risk to FDRs personalized to genotype, autoantibody results, and lifestyle risks resulted in increased willingness to change behaviors related to RA. Personalized risk education incorporating factors beyond genetics may motivate health behavior changes in those at risk for chronic disease and could be widely disseminated using a web-based tool.


Disclosure: J. A. Sparks, None; M. D. Iversen, None; Z. Yu, None; N. A. Triedman, None; M. G. Prado, None; R. Miller Kroouze, None; S. S. Kalia, Helix, 5,SoundRocket, 5; E. A. Mody, None; S. M. Helfgott, None; D. J. Todd, None; P. F. Dellaripa, None; B. L. Bermas, None; K. D. Deane, Inova Diagnostics, Inc., 9; K. H. Costenbader, UpToDate, 7; B. Lu, None; R. C. Green, Invitae, 5,Prudential, 5,Illumina, 5,AIA, 5,Helix, 5,Roche Pharmaceuticals, 5; E. W. Karlson, None.

To cite this abstract in AMA style:

Sparks JA, Iversen MD, Yu Z, Triedman NA, Prado MG, Miller Kroouze R, Kalia SS, Mody EA, Helfgott SM, Todd DJ, Dellaripa PF, Bermas BL, Deane KD, Costenbader KH, Lu B, Green RC, Karlson EW. A Randomized Controlled Trial of Rheumatoid Arthritis Risk Disclosure Personalized to Genetics, Autoantibodies, and Lifestyle Among Unaffected First-Degree Relatives: The Personalized Risk Estimator for RA (PRE-RA) Family Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-randomized-controlled-trial-of-rheumatoid-arthritis-risk-disclosure-personalized-to-genetics-autoantibodies-and-lifestyle-among-unaffected-first-degree-relatives-the-personalized-risk-estimator-f/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-randomized-controlled-trial-of-rheumatoid-arthritis-risk-disclosure-personalized-to-genetics-autoantibodies-and-lifestyle-among-unaffected-first-degree-relatives-the-personalized-risk-estimator-f/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology